grekovВестник хирургии имени И.И. ГрековаGrekov's Bulletin of Surgery0042-46252686-7370Federal State Budgetary Educational Institution of Higher Education «Academician I.P. Pavlov First St. Petersburg State Medical University» of the Ministry of Healthcare of the Russion Federation, FSBEI HE I.P.Pavlov SPbSMU MOH Russia10.24884/0042-4625-2017-176-6-96-100grekov-380Research ArticleОБЗОРЫREVIEWSРИСК РАЗВИТИЯ ГЕМОРРАГИЧЕСКИХ ОСЛОЖНЕНИЙ ТЕРАПИИ ВАРФАРИНОМRisk of development of hemorrhagic complications due to warfarin therapyФилипповаО. И.FilippovaO. I.milidoctor@mail.ruКолосковА. В.KoloskovA. V.Andrei.Koloskov@szgmu.ruЧерноваЕ. В.ChernovaE. V.katerynachernova@mail.ruСеверо-Западный государственный медицинский университет им. И. И. МечниковаРоссияI. I. Mechnikov North-Western State Medical UniversityRussian Federation201728122017176696100Copyright © Филиппова О.И., Колосков А.В., Чернова Е.В., 20172017Филиппова О.И., Колосков А.В., Чернова Е.В.Filippova O.I., Koloskov A.V., Chernova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.vestnik-grekova.ru/jour/article/view/380варфарингипокоагуляциякровотечениеwarfarinhypocoagulationhaemorrhageReferencesЗадионченко В. С., Шехян Г. Г., Щикота А. М., Ялымов А. А. Место Варфарина в лечении и профилактике тромбоэмболий // Российский медицинский журнал. 2011. № 26. С. 1648- 1651.Задионченко В. С., Шехян Г. Г., Щикота А. М., Ялымов А. А. Место Варфарина в лечении и профилактике тромбоэмболий // Российский медицинский журнал. 2011. № 26. С. 1648- 1651.Румянцев Н. А., Сычёв Д. А., Кукес В. Г. Перспективы индивидуализации применения и дозирования пероральных антикоагулянтов и статинов у пациентов в рутинной клинической практике // Клин. фармакол. и терапия. 2015. Т. 96, № 6. С. 1065-1068.Румянцев Н. А., Сычёв Д. А., Кукес В. Г. Перспективы индивидуализации применения и дозирования пероральных антикоагулянтов и статинов у пациентов в рутинной клинической практике // Клин. фармакол. и терапия. 2015. Т. 96, № 6. С. 1065-1068.Шевела А. И., Лифшиц Г. И., Новикова Я. В., Севостьянова К. С. Фармакогенетические основы применения варфарина // Флебология. 2008. № 3. С. 35-37.Шевела А. И., Лифшиц Г. И., Новикова Я. В., Севостьянова К. С. Фармакогенетические основы применения варфарина // Флебология. 2008. № 3. С. 35-37.Anderson J. L., Horne B. D., Stevens S. M. et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation // Circulation. 2007. Vol. 116. P. 2563- 2570.Anderson J. L., Horne B. D., Stevens S. M. et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation // Circulation. 2007. Vol. 116. P. 2563- 2570.Baker W. L., Johnson S.l. G Pharmacogenetics and oral anti-thrombotic drugs // Current Opinion in Pharmacology. 2016. Vol. 27. P. 38-42.Baker W. L., Johnson S.l. G Pharmacogenetics and oral anti-thrombotic drugs // Current Opinion in Pharmacology. 2016. Vol. 27. P. 38-42.Beyth R. J., Quinn L. M., Landefeld C. S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin // Amer. J. Med. 1998. Vol. 105, № 2. P. 91-99.Beyth R. J., Quinn L. M., Landefeld C. S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin // Amer. J. Med. 1998. Vol. 105, № 2. P. 91-99.Bloomfield H. E., Taylor B. C., Krause A. et al. Safe and effective anticoagulation in the outpatient setting : a systematic review of the evidence. VA Evidence-based Synthesis Program (ESP) Medical CenterWashington (DC) : Department of Veterans Affairs (US). Washington, 2011.P. 20Bloomfield H. E., Taylor B. C., Krause A. et al. Safe and effective anticoagulation in the outpatient setting : a systematic review of the evidence. VA Evidence-based Synthesis Program (ESP) Medical CenterWashington (DC) : Department of Veterans Affairs (US). Washington, 2011.P. 20Bodin L., Verstuyft C., Tregouet D. A. et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity // Blood. 2005. Vol. 106, № 1. P. 135-140.Bodin L., Verstuyft C., Tregouet D. A. et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity // Blood. 2005. Vol. 106, № 1. P. 135-140.Burmester J. K., Berg R. L., Yale S. H. et al. A randomized controlled trial of genotype-based Coumadin initiation // Genet Med. 2011. Vol. 13. P. 509-518.Burmester J. K., Berg R. L., Yale S. H. et al. A randomized controlled trial of genotype-based Coumadin initiation // Genet Med. 2011. Vol. 13. P. 509-518.Caraco Y., Blotnick S., Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the еfficacy and safety of anticoagulation: a prospective randomized controlled study // Clin. Pharmacol. Ther. 2008. Vol. 83. P. 460-470.Caraco Y., Blotnick S., Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the еfficacy and safety of anticoagulation: a prospective randomized controlled study // Clin. Pharmacol. Ther. 2008. Vol. 83. P. 460-470.Crespi C., Miller V. The R144C change in the CYP2C9*2 allele alters interaction of the cytochromeP450 with NADPH: cytochrome P450 oxidoreductase // Pharmacogenetics. 1997. Vol. 7. P. 203-210.Crespi C., Miller V. The R144C change in the CYP2C9*2 allele alters interaction of the cytochromeP450 with NADPH: cytochrome P450 oxidoreductase // Pharmacogenetics. 1997. Vol. 7. P. 203-210.Donze´ J., Clair C., Hug B. et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy // Amer. J. Med. 2012. Vol. 125, № 8. P. 773-778.Donze´ J., Clair C., Hug B. et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy // Amer. J. Med. 2012. Vol. 125, № 8. P. 773-778.Fang M. C., Go A. S., Chang Y. et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages // Amer. J. Med. 2007. Vol. 120, № 8. P. 700-705.Fang M. C., Go A. S., Chang Y. et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages // Amer. J. Med. 2007. Vol. 120, № 8. P. 700-705.Fang M. C., Go A. S., Chang Y. et al. A new risk scheme to predict warfarin-associated hemorrhage the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study // J. Am. Coll Cardiol. 2011. Vol. 58. P. 395-401.Fang M. C., Go A. S., Chang Y. et al. A new risk scheme to predict warfarin-associated hemorrhage the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study // J. Am. Coll Cardiol. 2011. Vol. 58. P. 395-401.Fang M. C., Go A. S., Hylek E. M. et al. Age and the risk of war-fa rin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study // J. Am. Geriatr. Soc. 2006. Vol. 54. P. 1231-1236.Fang M. C., Go A. S., Hylek E. M. et al. Age and the risk of war-fa rin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study // J. Am. Geriatr. Soc. 2006. Vol. 54. P. 1231-1236.Gomberg-Maitland M., Wenger N. K., Feyzi J. et al. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials // Eur. Heart J. 2006. Vol. 27, № 16. P. 1947-1953.Gomberg-Maitland M., Wenger N. K., Feyzi J. et al. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials // Eur. Heart J. 2006. Vol. 27, № 16. P. 1947-1953.Haining R., Hunter A., Veronese M. et al. Allelic variants of human cytochrome P4502C9 : baculovirus-mediated expression purification,structural characterisation, substrate streoselectivity and prochiral selectivity of the wild-type and I359L mutant forms // Arch. Biochem. Biophys. 1996. Vol. 333, № 2. P. 447-458.Haining R., Hunter A., Veronese M. et al. Allelic variants of human cytochrome P4502C9 : baculovirus-mediated expression purification,structural characterisation, substrate streoselectivity and prochiral selectivity of the wild-type and I359L mutant forms // Arch. Biochem. Biophys. 1996. Vol. 333, № 2. P. 447-458.Higashi M. K., Veenstra D. L., Kondo L. M. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy // J. A. M. A. 2002. Vol. 287, № 13. P. 1690-1698.Higashi M. K., Veenstra D. L., Kondo L. M. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy // J. A. M. A. 2002. Vol. 287, № 13. P. 1690-1698.Holbrook A. M., Pereira J. A., Labiris R. et al. Systematic overview of warfarin and its drug and food interactions // Arch. Intern. Med. 2005. Vol. 165, № 10. P. 1095-1106.Holbrook A. M., Pereira J. A., Labiris R. et al. Systematic overview of warfarin and its drug and food interactions // Arch. Intern. Med. 2005. Vol. 165, № 10. P. 1095-1106.Kamali F., Pirmohamed M. The future prospects of pharmacogenetics in oral anticoagulation therapy // Brit. J. Clin. Pharmacol. 2006. Vol. 61, № 6. Р. 746-751.Kamali F., Pirmohamed M. The future prospects of pharmacogenetics in oral anticoagulation therapy // Brit. J. Clin. Pharmacol. 2006. Vol. 61, № 6. Р. 746-751.Kimmel S. E., French B., Kasner S. E. et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing // N. Engl. J. Med. 2013. Vol. 369, № 24. P. 2283-2293.Kimmel S. E., French B., Kasner S. E. et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing // N. Engl. J. Med. 2013. Vol. 369, № 24. P. 2283-2293.Limdi N. A., McGwin G., Goldstein J. A. et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin // Clin. Pharmacol. Ther. 2008. Vol. 83, № 2. P. 312-321.Limdi N. A., McGwin G., Goldstein J. A. et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin // Clin. Pharmacol. Ther. 2008. Vol. 83, № 2. P. 312-321.Lind M., Boman K., Johansson L. et al. Thrombomodulin as a marker for bleeding complications during warfarin treatment // Arch. Intern. Med. 2009. Vol. 169, № 13. P. 1210-1215.Lind M., Boman K., Johansson L. et al. Thrombomodulin as a marker for bleeding complications during warfarin treatment // Arch. Intern. Med. 2009. Vol. 169, № 13. P. 1210-1215.Lindh J. D., Holm L., Dahl M. L. et al. Incidence and predictors of severe bleeding during warfarin treatment // J. Thromb. Thrombolysis. 2008. Vol. 5, № 2. P. 151-159.Lindh J. D., Holm L., Dahl M. L. et al. Incidence and predictors of severe bleeding during warfarin treatment // J. Thromb. Thrombolysis. 2008. Vol. 5, № 2. P. 151-159.Lip G. Y., Frison L., Halperin J. L. et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation : the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score // J. Am. Coll. Cardiol. 2011. Vol. 57, № 2. P. 173-180.Lip G. Y., Frison L., Halperin J. L. et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation : the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score // J. Am. Coll. Cardiol. 2011. Vol. 57, № 2. P. 173-180.McMahan D. A., Smith D. M., Carey M. A. et al. Risk of major hemorrhage for outpatients treated with warfarin // J. Gen. Intern. Med. 1998. Vol. 13. P. 311-316.McMahan D. A., Smith D. M., Carey M. A. et al. Risk of major hemorrhage for outpatients treated with warfarin // J. Gen. Intern. Med. 1998. Vol. 13. P. 311-316.Meckley L. M., Wittkowsky A. K., Rieder M. J. et al. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients // Thromb. Haemost. 2008. Vol. 100, № 2. P. 229-239.Meckley L. M., Wittkowsky A. K., Rieder M. J. et al. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients // Thromb. Haemost. 2008. Vol. 100, № 2. P. 229-239.Mohamed H. A., Johnson S. J., Johnson A. Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice? // Curr. Opin. Cardiol. 2013. Vol. 28, № 3. P. 305-314.Mohamed H. A., Johnson S. J., Johnson A. Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice? // Curr. Opin. Cardiol. 2013. Vol. 28, № 3. P. 305-314.Moyer T. P., O’Kane D. J., Linnea M. et al. Warfarin sensitivity genotyping : a review of the literature and summary of patient experience // Mayo Clin. Proc. 2009. Vol. 84, № 12. P. 1079-1094.Moyer T. P., O’Kane D. J., Linnea M. et al. Warfarin sensitivity genotyping : a review of the literature and summary of patient experience // Mayo Clin. Proc. 2009. Vol. 84, № 12. P. 1079-1094.Patrick A. R., Avorn J., Choudhry N. K. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation // Circ. Cardiovasc. Qual. Outcomes. 2009. Vol. 2. P. 429-436.Patrick A. R., Avorn J., Choudhry N. K. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation // Circ. Cardiovasc. Qual. Outcomes. 2009. Vol. 2. P. 429-436.Pink J., Pirmohamed M., Lane S. et al. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation // Clin. Pharmacol. Ther. 2014. Vol. 95. P. 199-207.Pink J., Pirmohamed M., Lane S. et al. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation // Clin. Pharmacol. Ther. 2014. Vol. 95. P. 199-207.Roth J. A., Bradley K., Thummel K. E. et al. Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting // Pharmacoepidemiol. Drug. Saf. 2015. Vol. 24, № 6. P. 619-627.Roth J. A., Bradley K., Thummel K. E. et al. Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting // Pharmacoepidemiol. Drug. Saf. 2015. Vol. 24, № 6. P. 619-627.Schalekamp T., Brassé B. P., Roijers J. F. et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation // Clin. Pharmacol. Ther. 2006. Vol. 80. P. 13-22Schalekamp T., Brassé B. P., Roijers J. F. et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation // Clin. Pharmacol. Ther. 2006. Vol. 80. P. 13-22Schauer D. P., Moomaw C. J., Wess M. et al. Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin // J. Gen. Intern. Med. 2005. Vol. 20, № 12. P. 1114-1119.Schauer D. P., Moomaw C. J., Wess M. et al. Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin // J. Gen. Intern. Med. 2005. Vol. 20, № 12. P. 1114-1119.Shireman T.I., Mahnken J. D., Howard P.A. et al. Development of a contemporary bleeding risk model for elderly warfarin recipients // Chest. 2006. Vol. 130, № 5. P. 1390-1396.Shireman T.I., Mahnken J. D., Howard P.A. et al. Development of a contemporary bleeding risk model for elderly warfarin recipients // Chest. 2006. Vol. 130, № 5. P. 1390-1396.Singer D. E., Chang Y., Fang M. C. et al. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation? The ATRIA study// Circ. Cardiovasc. Qual. Outcomes. 2009. Vol. 2, № 4. P. 297-304.Singer D. E., Chang Y., Fang M. C. et al. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation? The ATRIA study// Circ. Cardiovasc. Qual. Outcomes. 2009. Vol. 2, № 4. P. 297-304.Suzuki S., Yamashita T., Kato T. et al. Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation // Circ. J. 2007. Vol. 71. P. 761-765.Suzuki S., Yamashita T., Kato T. et al. Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation // Circ. J. 2007. Vol. 71. P. 761-765.Taube J., Halsall D., Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment // Blood. 2000. Vol. 96, № 5. P. 1816-1819.Taube J., Halsall D., Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment // Blood. 2000. Vol. 96, № 5. P. 1816-1819.Wang M., Lang X., Cui S. et al. Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: a randomized and controlled trial // Int. J. Med. Sci. 2012. Vol. 9. P. 472-479.Wang M., Lang X., Cui S. et al. Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: a randomized and controlled trial // Int. J. Med. Sci. 2012. Vol. 9. P. 472-479.Wynne H. et al. The influence of age, liver size and enantiomer concentrations on warfarin requirements // Brit. J. Clin. Pharmacol. 1995. Vol. 40. P. 203-207.Wynne H. et al. The influence of age, liver size and enantiomer concentrations on warfarin requirements // Brit. J. Clin. Pharmacol. 1995. Vol. 40. P. 203-207.Wysowski D. K., Nourjah P., Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action // Arch. Intern. Med. 2007. Vol. 167. P. 1414-1419.Wysowski D. K., Nourjah P., Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action // Arch. Intern. Med. 2007. Vol. 167. P. 1414-1419.Yang J., Chen Y., Li X. et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis // Int. J. Cardiol. 2013. Vol. 168. P. 4234-4243.Yang J., Chen Y., Li X. et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis // Int. J. Cardiol. 2013. Vol. 168. P. 4234-4243.
The authors declare that there are no conflicts of interest present.